Novel use of liver x receptor agonists

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/00 (2006.01) A61K 31/18 (2006.01) A61K 31/195 (2006.01) A61P 3/10 (2006.01)

Patent

CA 2608052

The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist.

Cette invention concerne de façon générale une nouvelle utilisation thérapeutique des agonistes du récepteur X du foie (LXR). Plus spécifiquement, cette invention concerne l'utilisation d'un agoniste du récepteur LXR pour la préparation d'un médicament servant au traitement et/ou à la prévention des maladies associées à la dégénérescence des cellules bêta, telles que le diabète, ainsi qu'un procédé permettant d'accroître la viabilité ex vivo des cellules dites îlots de Langerhans et consistant à mettre ces cellules en contact avec un agoniste de LXR.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel use of liver x receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel use of liver x receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel use of liver x receptor agonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2005881

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.